BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, Graupera I, Martín-llahí M, Ariza X, Cárdenas A, Fernández J, Rodés J, Arroyo V, Ginès P. Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. Hepatology 2014;59:1505-13. [DOI: 10.1002/hep.26687] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Nickovic VP, Miric D, Kisic B, Kocic H, Stojanovic M, Buttice S, Kocic G. Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. Ren Fail 2018;40:340-9. [PMID: 29658815 DOI: 10.1080/0886022X.2018.1459699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Graupera I, Solà E, Fabrellas N, Moreira R, Solé C, Huelin P, de la Prada G, Pose E, Ariza X, Risso A, Albertos S, Morales-Ruiz M, Jiménez W, Ginès P. Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS One 2016;11:e0157371. [PMID: 27359339 DOI: 10.1371/journal.pone.0157371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 Altun R, Korkmaz M, Yıldırım E, Öcal S, Akbaş E, Selçuk H. Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus 2015;4:806. [PMID: 26722626 DOI: 10.1186/s40064-015-1625-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Durand F, Graupera I, Ginès P, Olson JC, Nadim MK. Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis 2016;67:318-28. [PMID: 26500178 DOI: 10.1053/j.ajkd.2015.09.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
5 Olson JC, Karvellas CJ. Critical care management of the patient with cirrhosis awaiting liver transplant in the intensive care unit. Liver Transpl 2017;23:1465-76. [DOI: 10.1002/lt.24815] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
6 Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT. Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology. 2019;69:729-741. [PMID: 30141205 DOI: 10.1002/hep.30230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Tapper EB, Bonder A, Cardenas A. Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. The American Journal of Medicine 2016;129:461-7. [DOI: 10.1016/j.amjmed.2015.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Gifford FJ, Fallowfield JA. Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach? Aliment Pharmacol Ther 2017;46:193-4. [PMID: 28621082 DOI: 10.1111/apt.14098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Salerno F, Monti V. Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis. Hepatology. 2014;59:1239-1241. [PMID: 24425447 DOI: 10.1002/hep.27015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
12 Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Seminars in Nephrology 2019;39:17-30. [DOI: 10.1016/j.semnephrol.2018.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
13 Sheng XY, Lin FY, Wu J, Cao HC. Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study. World J Gastroenterol 2021; 27(20): 2615-2629 [PMID: 34092979 DOI: 10.3748/wjg.v27.i20.2615] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Zhang X, Xu X, Jiang Y, He J, Wang W, Li W, Zhang X, Lv Y. Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome. Oncotarget 2017;8:109258-70. [PMID: 29312606 DOI: 10.18632/oncotarget.22668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Sobhonslidsuk A. Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J Gastrointest Pharmacol Ther 2015; 6(3): 28-31 [PMID: 26261732 DOI: 10.4292/wjgpt.v6.i3.28] [Reference Citation Analysis]
16 Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015;2015:108139. [PMID: 26266048 DOI: 10.1155/2015/108139] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
17 Karvellas CJ, Francoz C, Weiss E. Liver Transplantation in Acute-on-chronic Liver Failure. Transplantation 2021;105:1471-81. [PMID: 33208692 DOI: 10.1097/TP.0000000000003550] [Reference Citation Analysis]
18 Gleeson MW, Dickson RC. Albumin gains immune boosting credibility. Clin Transl Gastroenterol. 2015;6:e86. [PMID: 25928809 DOI: 10.1038/ctg.2015.11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014; 20(10): 2542-2554 [PMID: 24627590 DOI: 10.3748/wjg.v20.i10.2542] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
20 Theocharidou E, Agarwal B, Jeffrey G, Jalan R, Harrison D, Burroughs AK, Kibbler CC. Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit. Clin Microbiol Infect 2016; 22: 189.e1-189. e7. [PMID: 26551838 DOI: 10.1016/j.cmi.2015.10.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
21 Abdel-Razik A, Mousa N, Abdelsalam M, Abdelwahab A, Tawfik M, Tawfik AM, Hasan AS, Elhelaly R, El-Wakeel N, Eldars W. Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome. Front Pharmacol 2020;11:9. [PMID: 32076410 DOI: 10.3389/fphar.2020.00009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Michelena J, Altamirano J, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán JC, Fernández J, Arroyo V. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62:762-772. [PMID: 25761863 DOI: 10.1002/hep.27779] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 24.2] [Reference Citation Analysis]
23 Maiwall R, Chandel SS, Wani Z, Kumar S, Sarin SK. SIRS at Admission Is a Predictor of AKI Development and Mortality in Hospitalized Patients with Severe Alcoholic Hepatitis. Dig Dis Sci 2016;61:920-9. [PMID: 26470868 DOI: 10.1007/s10620-015-3921-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
24 Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
25 Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int 2016;10:245-57. [DOI: 10.1007/s12072-015-9652-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
26 Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int. 2016;10:115-123. [PMID: 26141259 DOI: 10.1007/s12072-015-9641-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
27 Maiwall R, Pasupuleti SSR, Chandel SS, Narayan A, Jain P, Mitra LG, Kumar G, Moreau R, Sarin SK. Co-orchestration of acute kidney injury and non-kidney organ failures in critically ill patients with cirrhosis. Liver Int 2021;41:1358-69. [PMID: 33534915 DOI: 10.1111/liv.14809] [Reference Citation Analysis]
28 Oliveira AM, Branco JC, Barosa R, Rodrigues JA, Ramos L, Martins A, Karvellas CJ, Cardoso FS. Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2016;28:1216-1222. [PMID: 27391170 DOI: 10.1097/meg.0000000000000700] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
29 Nadim MK, Durand F, Kellum JA, Levitsky J, O’leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent J, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology 2016;64:717-35. [DOI: 10.1016/j.jhep.2015.10.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 111] [Article Influence: 30.0] [Reference Citation Analysis]
30 Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol 2015; 7(17): 2058-2068 [PMID: 26301048 DOI: 10.4254/wjh.v7.i17.2058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
31 Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? Kidney Int. 2017;92:1058-1070. [PMID: 28844314 DOI: 10.1016/j.kint.2017.04.048] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
32 Karvellas CJ, Durand F, Nadim MK. Acute Kidney Injury in Cirrhosis. Critical Care Clinics 2015;31:737-50. [DOI: 10.1016/j.ccc.2015.06.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
33 Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol 2018;16:162-177.e1. [PMID: 28602971 DOI: 10.1016/j.cgh.2017.05.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
34 Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87:509-515. [PMID: 25296092 DOI: 10.1038/ki.2014.338] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 7.1] [Reference Citation Analysis]
35 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4:23. [PMID: 30213943 DOI: 10.1038/s41572-018-0022-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 18.7] [Reference Citation Analysis]
36 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
37 Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14:55-66. [PMID: 27924081 DOI: 10.1038/nrgastro.2016.168] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 33.6] [Reference Citation Analysis]
38 Arora A, Kumar A, Prasad N, Duseja A, Acharya SK, Agarwal SK, Aggarwal R, Anand AC, Bhalla AK, Choudhary NS, Chawla YK, Dhiman RK, Dixit VK, Gopalakrishnan N, Gupta A, Hegde UN, Jasuja S, Jha V, Kher V, Kumar A, Madan K, Maiwall R, Mathur RP, Nayak SL, Pandey G, Pandey R, Puri P, Rai RR, Raju SB, Rana DS, Rao PN, Rathi M, Saraswat VA, Saxena S, Shalimar, Sharma P, Singh SP, Singal AK, Soin AS, Taneja S, Varughese S. INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 2021;11:354-86. [PMID: 33994718 DOI: 10.1016/j.jceh.2020.09.005] [Reference Citation Analysis]
39 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]